Type of PTM# of patients with tumors (% incidence) |
|
Transplant |
|
Reference |
Organ |
# pts |
# PatientsPTM |
Tumor site |
Skin (includesKS) |
HLM inclPTLD |
NCNLtumor |
Kellerman [14] |
H |
851 |
73(8.6%) |
- |
6(8%) |
- |
67(92%) |
Favaloro [15] |
H |
309 |
11(3.5%) |
- |
- |
11(100%) |
- |
Alam [16] |
H |
6,271 |
440(7%) |
Skin |
440(100%) |
- |
- |
Caforio [17] |
H |
488 |
51(10%) |
- |
NR |
17(30%) |
34(70%) |
Crespo-Leiro [18] |
H |
4,357 |
102(2.3%) |
Lu |
|
- |
102(100%) |
Hamour [19] |
H |
399 |
108(27%) |
- |
52(48%) |
40(37%) |
16(15%) |
Crespo-Leiro [20] |
H |
3,393 |
639(19%) |
- |
324(51%) |
62(10%) |
253(39%) |
Jiang [21] |
H |
1,703 |
160(9.4%) |
- |
NR |
59(37%) |
101(63%) |
Hsu [22] |
H |
291 |
17(5.8%) |
- |
3(18%) |
7(41%) |
7(41%) |
Molina [23] |
H |
3,393 |
324(9.5%) |
Skin |
324(100%) |
- |
- |
Sanchez-Lazaro [24] |
H |
597 |
109(18.3%) |
- |
62(57%) |
9(8%) |
38(35%) |
PTM, posttransplant malignancy, KS Kaposi’s sarcoma, HLM hematolymphoid malignancy, NCNL, non-cutaneous non-lymphomatous, H heart transplant, NR, not reported,
Lu Lung |